Omapatrilat

CAS No. 167305-00-2

Omapatrilat( BMS-186716 )

Catalog No. M12553 CAS No. 167305-00-2

A potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 74 Get Quote
50MG 512 Get Quote
100MG 896 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Omapatrilat
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively.
  • Description
    A potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively; shows moderate activity against APP, and low activity against ECE1; causes significant inhibition of plasma ACE and increases plasma renin activity, reduces blood pressure in spontaneously hypertensive rats; orally active.Hypertension Discontinued.
  • In Vitro
    Omapatrilat exhibits high potency for NEP, NEP2 and ACE, moderate strong activity against APP, but low activity against ECE1 (Ki=0.45, 25, 0.64, 250 nM) . In vitro autoradiography using the specific NEP inhibitor radioligand 125I-RB104 and the specific ACE inhibitor radioligand 125I-MK351A show omapatril at (10 mg/kg) causes rapid and potent inhibition of renal NEP and ACE, respectively, for 24 h.
  • In Vivo
    Omapatrilat demonstrates excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiates urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. Omapatrilat decreases mean arterial pressure (MAP) approximately 40 mmHg below baseline from 10 to 24 h. Oral administration of omapatrilat at 100 μM/kg once daily results in a 38 mmHg decrease in systolic blood pressure at day three as compared to vehicle . Omapatrilat is widely used in experimental protocols related to hypertension and heart failure. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. Omapatrilat causes significant inhibition of plasma ACE and increased plasma renin activity in rats.
  • Synonyms
    BMS-186716
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    ACE
  • Recptor
    ACE
  • Research Area
    Cardiovascular Disease
  • Indication
    Hypertension

Chemical Information

  • CAS Number
    167305-00-2
  • Formula Weight
    408.5349
  • Molecular Formula
    C19H24N2O4S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 31 mg/mL
  • SMILES
    O=C([C@@H]1CCC[C@](N21)([H])SCC[C@H](NC([C@@H](S)CC3=CC=CC=C3)=O)C2=O)O
  • Chemical Name
    7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-, (4S,7S,10aS)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Robl JA, et al. J Med Chem. 1997 May 23;40(11):1570-7. 2. Fryer RM, et al. Br J Pharmacol. 2008 Mar;153(5):947-55. 3. Burrell LM, et al. Am J Hypertens. 2000 Oct;13(10):1110-6.
molnova catalog
related products
  • Lisinopril dihydrate

    A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.

  • Zabicipril HCl

    Zabicipril HCl(S 9650) is a potent angiotensin-converting enzyme inhibitor.

  • Temocaprilat

    Temocaprilat is an Angiotensin-converting Enzyme (ACE) inhibitor.